Dualyx is a Ghent-based biotech company that develops novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven.
investor of
Metrics
marketPRIVATE
msh_idCOM:DUALYX
localebe
websitehttps://www.dualyx.com
linkedinhttps://www.linkedin.com/company/dualyx
founding_date2021-01-01
source_ref1b14ebc6-5cf8-4638-9ad7-0ac6b221dfa9
company_size11
products_or_servicesDevelopment of immune modulating programs, including DT-001 (an antibody agonist program targeting the TNF receptor 2) and additional Treg programs in early development.